candidate gene resequencing in a large bicuspid aortic valve-associated thoracic aortic aneurysm cohort: smad6 as an important contributor

Clicks: 205
ID: 234307
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #377 of 461 articles by views in Journal of clinical and experimental dentistry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 461 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Bicuspid aortic valve (BAV) is the most common congenital heart defect. Although many BAV patients remain asymptomatic, at least 20% develop thoracic aortic aneurysm (TAA). Historically, BAV-related TAA was considered as a hemodynamic consequence of the valve defect. Multiple lines of evidence currently suggest that genetic determinants contribute to the pathogenesis of both BAV and TAA in affected individuals. Despite high heritability, only very few genes have been linked to BAV or BAV/TAA, such as NOTCH1, SMAD6, and MAT2A. Moreover, they only explain a minority of patients. Other candidate genes have been suggested based on the presence of BAV in knockout mouse models (e.g., GATA5, NOS3) or in syndromic (e.g., TGFBR1/2, TGFB2/3) or non-syndromic (e.g., ACTA2) TAA forms. We hypothesized that rare genetic variants in these genes may be enriched in patients presenting with both BAV and TAA. We performed targeted resequencing of 22 candidate genes using Haloplex target enrichment in a strictly defined BAV/TAA cohort (n = 441; BAV in addition to an aortic root or ascendens diameter ≥ 4.0 cm in adults, or a Z-score ≥ 3 in children) and in a collection of healthy controls with normal echocardiographic evaluation (n = 183). After additional burden analysis against the Exome Aggregation Consortium database, the strongest candidate susceptibility gene was SMAD6 (p = 0.002), with 2.5% (n = 11) of BAV/TAA patients harboring causal variants, including two nonsense, one in-frame deletion and two frameshift mutations. All six missense mutations were located in the functionally important MH1 and MH2 domains. In conclusion, we report a significant contribution of SMAD6 mutations to the etiology of the BAV/TAA phenotype.
Reference Key
gillis2017frontierscandidate Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Elisabeth Gillis;Ajay A. Kumar;Ilse Luyckx;Christoph Preuss;Elyssa Cannaerts;Gerarda van de Beek;Björn Wieschendorf;Björn Wieschendorf;Maaike Alaerts;Nikhita Bolar;Geert Vandeweyer;Josephina Meester;Florian Wünnemann;Russell A. Gould;Rustam Zhurayev;Dmytro Zerbino;Salah A. Mohamed;Seema Mital;Luc Mertens;Hanna M. Björck;Anders Franco-Cereceda;Andrew S. McCallion;Lut Van Laer;Judith M. A. Verhagen;Ingrid M. B. H. van de Laar;Marja W. Wessels;Emmanuel Messas;Guillaume Goudot;Michaela Nemcikova;Alice Krebsova;Marlies Kempers;Simone Salemink;Toon Duijnhouwer;Xavier Jeunemaitre;Juliette Albuisson;Per Eriksson;Gregor Andelfinger;Harry C. Dietz;Harry C. Dietz;Aline Verstraeten;Bart L. Loeys;Bart L. Loeys;Mibava Leducq Consortium
Journal Journal of clinical and experimental dentistry
Year 2017
DOI
10.3389/fphys.2017.00400
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.